Larazotide Acetate Research & Studies
We track 20 published, PubMed-indexed studies for Larazotide Acetate, spanning 2012 to 2026. The research below includes 15 reviews, 4 clinical trials, 1 meta-analysis.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
15
Reviews
4
Clinical Trials
1
Meta-Analysis
Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration.
ReviewDamianos JA, Bledsoe A, et al.|Gut|2026
Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.
Clinical TrialYonker LM, Kane AS, et al.|Sci Transl Med|2025
New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review.
ReviewDipasquale V, Romano C|Healthcare (Basel)|2025
Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments.
ReviewGirbal-González M, Pérez-Cano FJ|Nutrients|2025
Celiac disease: Hope for new treatments beyond a gluten-free diet.
ReviewD'heedene M, Vanuytsel T, Wauters L|Clin Nutr|2024
Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions.
ReviewVeres-Székely A, Szász C, et al.|Int J Mol Sci|2023
Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials.
Meta-AnalysisHoilat GJ, Altowairqi AK, et al.|Clin Res Hepatol Gastroenterol|2022
Celiac Disease and Targeting the Molecular Mechanisms of Autoimmunity in COVID Pandemic.
ReviewAilioaie LM, Ailioaie C, et al.|Int J Mol Sci|2022
Larazotide acetate: a pharmacological peptide approach to tight junction regulation.
ReviewSlifer ZM, Krishnan BR, et al.|Am J Physiol Gastrointest Liver Physiol|2021
The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases.
ReviewTroisi J, Venutolo G, et al.|Curr Med Chem|2021
Current pharmacological approaches and potential future therapies for Celiac disease.
ReviewKulkarni A, Patel S, et al.|Eur J Pharmacol|2021
The tight junction and the epithelial barrier in coeliac disease.
ReviewJauregi-Miguel A|Int Rev Cell Mol Biol|2021
Therapeutic options for coeliac disease: What else beyond gluten-free diet?
ReviewCaio G, Ciccocioppo R, et al.|Dig Liver Dis|2020
Nondietary Therapies for Celiac Disease.
ReviewSerena G, Kelly CP, Fasano A|Gastroenterol Clin North Am|2019
Evolving Therapy for Celiac Disease.
ReviewYoosuf S, Makharia GK|Front Pediatr|2019
Novel Nondietary Therapies for Celiac Disease.
ReviewAlhassan E, Yadav A, et al.|Cell Mol Gastroenterol Hepatol|2019
The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate.
ReviewKhaleghi S, Ju JM, et al.|Therap Adv Gastroenterol|2016
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.
Clinical TrialLeffler DA, Kelly CP, et al.|Gastroenterology|2015
Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.
Clinical TrialKelly CP, Green PH, et al.|Aliment Pharmacol Ther|2013
A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.
Clinical TrialLeffler DA, Kelly CP, et al.|Am J Gastroenterol|2012